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Abstract
Breast cancer is the most prevalent cancer in American women. Dietary factors are thought to have a strong influ-
ence on breast cancer incidence. This study utilized a meal-feeding protocol with female Sprague-Dawley rats to
evaluate effects of two ratios of carbohydrate:protein on promotion and early progression of breast tissue carcino-
mas. Mammary tumors were induced by N-methyl-N-nitrosourea (MNU) at 52 d of age. Post-induction, animals
were assigned to consume either a low protein high carbohydrate diet (LPHC; 15% and 60% of energy, respec-
tively) or a high protein moderate carbohydrate diet (HPMC; 35% and 40% of energy, respectively) for 10 wk. Ani-
mals were fed 3 meals/day to mimic human absorption and metabolism patterns. The rate of palpable tumor
incidence was reduced in HPMC relative to LPHC (12.9 ± 1.4%/wk vs. 18.2 ± 1.3%/wk). At 3 wk, post-prandial serum
insulin was larger in the LPHC relative to HPMC (+136.4 ± 33.1 pmol/L vs. +38.1 ± 23.4 pmol/L), while at 10 wk
there was a trend for post-prandial IGF-I to be increased in HPMC (P = 0.055). There were no differences in tumor
latency, tumor surface area, or cumulative tumor mass between diet groups. The present study provides evidence
that reducing the dietary carbohydrate:protein ratio attenuates the development of mammary tumors. These find-
ings are consistent with reduced post-prandial insulin release potentially diminishing the proliferative environment
required for breast cancer tumors to progress.
Background
Breast cancer is the most common cancer in American
women, with over 40,000 annual deaths and nearly
200,000 estimated new cases in 2009 [1]. Given the high
prevalence of breast cancer and associated physical,
social, and psychological detriments [2], reducing cancer
incidence through modifiable risk factors such as nutri-
tion is a high public health priority. Estimates suggest
that cancer incidence could be reduced by ~1/3 through
modifications in diet, including changes in total energy
intake and diet content of fat, protein or carbohydrate
[3]. With increased attention on higher protein, low car-
bohydrate diets for weight management, secondary
effects of these diets on tumor development are impor-
tant to evaluate.
Some studies report that dietary protein, and particu-
larly consumption of animal protein, is linked to
increased risk of breast cancer [4,5]. However, recent
large-scale evaluations have failed to identify intakes of
meat, eggs, or dairy products as risk factors [6]. Conver-
sely, epidemiological studies have reported protective
effects of dietary protein on breast cancer incidence [7]
and mortality [8]. A recent case-controlled study sug-
gests that a dietary pattern including the highest relative
levels of animal protein is inversely associated with
breast cancer risk [9].
Evidence is now accumulating that dietary carbohy-
drates, glycemic load, and hyperinsulinemia are asso-
ciated with increased cancer risk [10,11] and mortality
[12]. Higher levels of circulating and post-prandial
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tion and tumor development [13] through upregulation
of the PI3K/Akt signal pathway which is implicated in
breast cancer promotion and tumorigenesis [14].
Furthermore, insulin stimulates the ovaries to produce
androgens [15], which have been linked to increased
breast cancer risk [16]. To our knowledge, no studies
have attempted to compare the effects of dietary protein
versus carbohydrates in an experimental model of breast
cancer.
We have previously demonstrated that feeding rats
diets with increased protein and reduced carbohydrates
enhances muscle insulin signaling and glucose uptake,
attenuates post-prandial hyperinsulinemia, and stimu-
lates skeletal muscle protein synthesis [17,18]. Our
experimental model uses a meal-feeding protocol with
three discrete meals each day to mimic human eating
patterns and allow for isolation of post-prandial meal
responses. This study examined the effects of feeding
diets differing in ratios of carbohydrate/protein, but
within the Dietary Reference Intake (DRI) acceptable
macronutrient distribution range, on tumor incidence,
size, and development, in a chemically-induced model of
breast cancer. We hypothesized that a diet with a
reduced carbohydrate:protein ratio would have a favor-




Female 45 d old Sprague-Dawley rats (n = 74; Harlan-
Teklad, Indianapolis, IN) with a mean body weight of
135 ± 4.8 g were housed individually in stainless steel
wire-bottomed cages and maintained at 24°C with 12 h
reverse light cycle (light: 1900-0700 h) and free access
to water. Rats were trained to consume three meals
each day using a modified AIN-93G diet [19] (60% of
energy from carbohydrate, 15% protein, and 25% fat;
LPHC) as the baseline control. The meal pattern con-
sisted of a 3 g breakfast meal (20% of total energy) con-
sumed between 0700-0720 h, followed by free access to
food between 1300-1400 h (~40% total energy) and
1800-1900 h (~40% total energy). At 52 d of age, ani-
mals were randomly assigned to consume either the
baseline low protein high carbohydrate diet (LPHC; n =
37) or a high protein moderate carbohydrate diet (40%
carbohydrate, 35% protein, and 25% fat; HPMC; n = 37)
(Table 1). Both diet treatments were isoenergetic.
Tumors were induced in all animals at 52 d of age by a
single intraperitoneal dose of N-methyl-N-nitrosourea
( M N U )a t5 0m g / k gb o d yw e i g h ti n1m lo f0 . 9 %N a C l
[20]. Rats were weighed and food intake measured each
week. The animal protocol was approved by the Univer-
sity of Illinois Institutional Animal Care and Use
Committee.
Measurements
At 3 wk post-MNU treatment, rats were randomly
selected from LPHC (n = 12) and HPMC (n = 12)
groups and evaluated for metabolic changes associated
with diet treatments prior to tumor appearance. Rats
were euthanized either after overnight food deprivation
(fasted) or 90 min following consumption of a 3 g
breakfast meal. Trunk blood was collected in K3EDTA
vacutainers (BD, Franklin Lakes, NJ), placed on ice, and
subsequently centrifuged at 1500 × G at 4°C for 20 min.
Plasma was decanted and stored at -80°C for further
analysis. Soleus and gastrocnemius muscles of the left
leg were rapidly excised and frozen in liquid nitrogen,
while the soleus and gastrocnemius of the right leg were
dissected and weighed. Likewise, the left retroperitoneal
fat pad was excised and frozen and the right retroperito-
neal fat pad dissected and weighed. Liver was excised,
weighed, and frozen. The 3 wk time point was intended
to capture metabolic differences that could affect tumor
promotion, while avoiding confounding pathology asso-
ciated with tumor development.
At 10 wk post-induction, rats from LPHC (n = 12)
and HPMC (n = 12) were measured for body fat using
dual-energy X-ray absorptiometery (DXA) (Hologic,
Inc., Bedford, MA). To isolate diet effects on body com-
position, only rats without palpable tumors were
scanned. Rats were sedated with medetomidine hydro-
chloride (Orion, Espoo, Finland) at 0.3 mg/kg body
weight 10 min prior to scanning, and were revived with
atipamezole (Orion, Espoo, Finland) at 0.15 mg/kg body
weight following the scan. All rats (LPHC: n = 25;
HPMC: n = 25) were euthanized in a similar manner 3-
Table 1 Diet Composition for Treatment Groups
Diet Component LPHC HPMC




Soybean Oil 116.24 116.24
t-Butylhydroquinone 0.014 0.014
Choline 2.5 2.5
AIN93G Minerals 35 35
AIN93G Vitamins 10 10
Cellulose 50 50
Cystine 2.36 2.36
Grams per kg diet. LPHC and HPMC represent low protein and high protein
diet groups, respectively.
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Page 2 of 74 d after DXA scanning and blood, soleus and gastro-
cnemius muscles, adipose, and liver were collected and
weighed as previously described. Mammary tumors were
rapidly excised, weighed, rinsed in saline, and a portion
was fixed for 24 hr in 10% neutral buffered formalin for
histological analysis. Fixed tumors were stored in 75%
ethanol, then subsequently dehydrated and imbedded in
paraffin. Imbedded tumors were then sectioned at 2-4
μM and stained with hematoxylin and eosin. Tumor
sections were graded histologically on the following
semi-quantitative scale: 0 - low grade adenocarcinoma, 1
- high grade adenocarcinoma, 2 - mild mammary hyper-
plasia, 3 - marked mammary hyperplasia.
Carcinogenesis Parameters
Animals were monitored for mammary tumor appearance
beginning at 5 wk post-induction through the remainder
of the study and after animal euthanasia. Rats were pal-
pated for mammary tumors 2 times/wk. When a tumor
was detected, the date and tumor location were recorded.
Tumor incidence and latency to tumor appearance were
determined qualitatively by palpation. Tumor dimensions
of length and width were measured orthogonally by cali-
per. Tumor surface area was calculated by the following
formula: 4π × (length/2) × (width/2). Following euthana-
sia, all tumors were excised and weighed.
Metabolic Analyses
Plasma glucose was measured by glucose oxidase assay
(Thermo, Waltham, MA). Plasma insulin was measured
by commercial RIA kit (Millipore, Billerica, MA). Plasma
IGF-I was measured by RIA after dissociation from
IGFBP by Sephadex G-50 chromatography in 0.2 M for-
mic acid. Eluant containing the free IGF was collected
and lyophilized (Labconco Freeze Dry Systems, Kansas
City, MO). IGF-I concentrations were measured using
[
125I]-IGF-I as a competitive radioligand and a polyclo-
nal anti-human antibody (National Hormone and Pitui-
tary Program, NIDDK, Torrance, CA). Bound
radioactivity was measured using a gamma counter
(Packard Instruments, Meriden, CT) and concentrations
were determined relative to a standard curve prepared
with recombinant human IGF-I [21].
Statistical Analysis
Data are expressed as mean ± SEM. Plasma glucose,
insulin, and IGF-I were analyzed using 2-way ANOVA
and between-diet differences were evaluated at each
time point. Tumor incidence and time of appearance
were evaluated using linear regression analysis. Histolo-
gical classification of excised tumors was analyzed with
a Mann-Whitney U test. All other carcinogenesis para-
meters, as well as body weight and food intake were
analyzed by a Student’s t-test. The level of significance
was set at P < 0.05. All analyses were performed using
SPSS Version 15.0 (Chicago, IL).
Results
Animal Weight Gain, Food Intake, and Body Composition
Body weights of HPMC and LPHC groups were not dif-
ferent at baseline (Figure 1). At 3 wk, there were no dif-
ferences between groups in body weight or weights of
gastrocnemius, soleus, or retroperitoneal fat pad (Table
2). Body weight was greater in the HPMC group at wks
3, 5-7, and 9-10 (P < 0.05) (Figure 1). There were no
differences in food intake between groups at any time
during the study. At 10 wk, there were no differences in
gastrocnemius or soleus weights between diet groups
(Table 2) or in % body fat measured by DXA. However,
retroperitoneal fat and liver were heavier in the HPMC
group.
Serum Glucose, Insulin, & IGF-I Concentrations
Serum glucose was not different between groups at 3 or
10 wk (Table 3) in either fasted or post-prandial blood
samples. At 3 wk, fasting insulin tended to be higher in
the HPMC group (P = 0.09), while the meal response of
serum insulin was greater in the LPHC group compared
to HPMC group (+136.4 ± 33.1 pmol/L vs. +38.1 ± 23.4
pmol/L, respectively; P = 0.035). At 10 wk, post-prandial
serum insulin was elevated in both LPHC and HPMC
groups compared to fasted animals. Serum IGF-I was
not significantly modified by diet or meal-feeding at 3
w k .A t1 0w kt h e r ew a sat r e n df o rs e r u mI G F - It ob e
increased post-prandially in the HPMC group (P =
0.055).
Carcinogenesis Parameters
At 3 wk post-induction, no animals had palpable tumors
and no tumors were found during dissection. Initial
palpable tumors were detected at 51 d in the LPHC
g r o u pa n d5 5di nt h eH P M Cg r o u p .S u r f a c ea r e ao f
palpable tumors was not different between treatments at
any time point. The rate of tumor incidence was higher
in the LPHC group with relative slopes of tumor inci-
dence of 18.2 ± 1.3%/wk and 12.9 ± 1.4%/wk (P <0 . 0 5 )
for the LPHC and HPMC groups, respectively (Figure
2). Other characteristics of tumor incidence, tumor
latency (average time to first tumor development), and
cumulative tumor mass at 10 wk, were not different
between treatments (Table 4). All excised tumors were
confirmed histologically to be mammary ductal carcino-
mas, and there were no differences between groups in
the grade of the carcinomas.
Discussion
The objective of this study was to identify potential
effects of manipulating the dietary carbohydrate:protein
ratio on the promotion of MNU-induced breast cancer
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Page 3 of 7tumors. A major finding of our study is that a HPMC
diet with an reduced carbohydrate:protein ratio signifi-
cantly reduced the rate of incidence of palpable mam-
mary tumors. Although tumor latency was not different
between groups, once palpable tumors began to appear,
the rate of tumor appearance proceeded more rapidly in
the LPHC group. This suggests that either reduced diet-
ary carbohydrate or elevated dietary protein (or both),
can attenuate the early development of mammary
tumors. In agreement with our previous study [17],
post-prandial insulin at 3 wk was elevated in the LPHC
group and not in the HPMC group. Thus, animals in
the LPHC group were likely exposed to higher, repeated
elevations in serum insulin following each discrete meal
during the period leading to the emergence of palpable
mammary tumors. Post-prandial insulin at 10 wk was
elevated in both groups, although host metabolism was
likely confounded by tumor pathology, and this change
does not necessarily diminish the early effect of post-
prandial insulin on tumor promotion.
Nearly two decades ago, hyperinsulinemia was identi-
fied as a significant risk factor for breast cancer,
independent of body composition or adiposity [22].
Cohort studies have found that women surgically treated
for breast cancer with high fasted insulin levels had sub-
stantially increased risk for reoccurrence and death [23]
and that the highest tertile of fasted insulin levels was
associated with a 2-fold increase in post-menopausal
breast cancer risk [24,25]. Most recently, the presence of
metabolic syndrome was reported to be associated with
breast cancer risk [26], and insulin resistance and post-
prandial hyperinsulinemia are central features of meta-
bolic syndrome [27], leading to suggestions that meta-
bolic syndrome may serve as a prognostic factor for
breast cancer [28]. With respect to dietary factors, a
positive association between high glycemic index/load
and breast cancer risk has been identified [29,30]. High
total carbohydrate intake [31] and sucrose intake have
been associated with unfavorable outcomes for breast
cancer.
One of the mechanisms by which insulin has been
proposed to increase breast cancer risk is via IGF-I. Ele-
vated insulin can increase serum free IGF-I concentra-
tions [32]. Overexpression of IGF-I in mammary
Figure 1 Body Weights; Values represent Means ± SEM. * indicates significant difference (P > 0.05).
Table 2 Body Composition Measures
LPHC HPMC Pvalue
Gastrocnemius weight (g) 3 wk 1.32 ± 0.03 1.32 ± 0.05 0.939
10 wk 1.54 ± 0.02 1.57 ± 0.03 0.398
Soleus weight (g) 3 wk 0.245 ± 0.006 0.237 ± 0.009 0.472
10 wk 0.299 ± 0.007 0.309 ± 0.006 0.281
Adipose weight (g) 3 wk 0.374 ± 0.056 0.358 ± 0.055 0.844
10 wk 0.443 ± 0.037 0.585 ± 0.047 0.021
Liver weight (g) 3 wk - - -
10 wk 5.60 ± 0.13 6.04 ± 0.11 0.012
% Body fat 10 wk 10.8 ± 0.6 11.2 ± 0.7 0.588
Values represent Mean ± SEM, n = 6 for each fasted and fed group.
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Page 4 of 7epithelium in vivo leads to hyperplasia, spontaneous
tumorogenesis, and enhanced susceptibility to chemical
carcinogens [33], and circulating IGF-I appears to be
important for the onset and subsequent development of
mammary tumorigenesis in in vivo experiments [34,35].
In the present study, the elevated post-prandial insulin
observed in the LPHC group was not associated with
increased serum IGF-I concentrations.
Clinically, the effect of IGF-I on breast cancer remains
equivocal. Elevated serum IGF-I concentrations appear
to increase risk of pre-, but not post-menopausal breast
cancer, while higher blood glucose levels were associated
with increased risk for developing post-menopausal
breast cancer [36]. However, a case control study identi-
fied a weak association for IGF-I with breast cancer in
women under the age of fifty [37]. Most recently, the
Women’s Health Initiative study found a strong associa-
tion between fasting insulin levels and breast cancer in
post-menopausal women, but no association of free
IGF-I [38].
IGF-I bioactivity is modulated by IGF binding proteins
(IGFBP), which can block IGF-I from binding to its
receptor. At least 75% of circulating IGF-I is bound to
IGFBP-3 [39], though IGFBP-3 levels remain fairly con-
stant within individuals [40]. IGFBP-1 and IGFBP-2
levels are inversely associated with insulin levels [41],
which suggests that chronic hyperinsulinemia could
depress binding protein interaction and thus increase
free IGF-I. Serum IGF-I levels have also been shown to
relate to protein intake [42]. In the present study at 10
wk, there was a trend for post-prandial IGF-I to be
higher (p = 0.055) in the HPMC group. Despite the ele-
vation of IGF-I in the HPMC group, the rate of tumor
incidence was significantly lower.
Consistent with our findings, early animal experiments
investigating the influence ofd i e t a r yp r o t e i no nb r e a s t
cancer found that feeding a higher protein diet prior to
administration of a carcinogen resulted in a reduction of
tumor prevalence [43], suggesting a protective effect of
protein during the initiation phase. Additionally,
Table 3 Plasma Metabolic Measurements
Fasted Fed Time Effect
PValue
Time × Diet Effect
P Value
Glucose (mmol/L) 3 wk LPHC 6.86 ± 0.50 6.74 ± 0.44 0.854 0.841
HPMC 7.16 ± 0.48 6.84 ± 0.47 0.642
10 wk LPHC 6.73 ± 0.18 6.54 ± 0.27 0.565 0.656
HPMC 6.70 ± 0.27 6.74 ± 0.31 0.917
Insulin (pmol/L) 3 wk LPHC 77.4 ± 11.6 213.8 ± 33.1 0.003 0.075
HPMC 125.1 ± 19.8 163.2 ± 23.4 0.350
10 wk LPHC 86.2 ± 10.4 194.4 ± 29.7 0.002 0.520
HPMC 77.5 ± 5.8 220.2 ± 37.6 0.003
IGF-I (μg/L) 3 wk LPHC 240 ± 24 272 ± 26 0.396 0.564
HPMC 274 ± 10 268 ± 32 0.917
10 wk LPHC 205 ± 30 211 ± 17 0.851 0.221
HPMC 237 ± 17 299 ± 23 0.055
Values represent Mean ± SEM, n = 6 for each fasted and fed group
Figure 2 Tumor Incidence; Comparison of slopes of linear regression (P = 0.019); LPHC: y = 18.10x - 119.3, r
2 = 0.968; HPMC:
y = 12.95x - 87.86, r
2 = 0.937.
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Page 5 of 7increased dietary protein fed after tumor induction had
no independent effect on the promotion phase of carci-
nogenesis [44]. In contrast to the findings of the present
study, Hawrylewicz et al. found higher dietary protein
(33% vs. 15%) increased the number of tumors and
tumor weight in MNU-induced rats, despite no differ-
ence in tumor incidence or latency [45]. However, this
study differed substantially from the current study in
that the rats were exposed in utero from dams fed the
test diets and then consumed the same test diets ad libi-
tum after weaning.
A further consideration is that elevated dietary protein
was accomplished at the expense of dietary carbohy-
drate, and since tumors are obligate glucose consumers,
HPMC may have been less energetically favorable to
neoplastic tissues. Similarly, a ketogenic diet (80% med-
ium chain triglycerides) fed to mice with implanted
colon adenocarcinomas reduced tumor weight, while the
inclusion of hydroxybutyrate in drinking water counter-
acted the stimulation of tumor growth by insulin infu-
sion [46]. However, fasted glucose was not different
between groups at either 3 or 10 wks, and in reflecting
current dietary guidelines, the HPMC diet was not low
enough in carbohydrate to induce ketogenesis.
A limitation of the current study is its relatively short
l e n g t h .A t1 0w k s ,t u m o ri n cidence had only reached
40% in the HPMC group. Due to the labor-intensive
nature of the meal-feeding protocol, this study was
designed for 10 wk, with a goal of both groups exceed-
ing 50% tumor incidence. However, within the short
period of time, the study still achieved divergent rates of
tumor appearance between diet groups.
Conclusion
In total, the present study provides evidence that redu-
cing the dietary carbohydrate:protein ratio attenuates
the progression of mammary tumors, and this finding is
consistent with reduced post-prandial insulin release
potentially diminishing the proliferative environment
required for breast cancer tumors to progress. These
results warrant additional investigation into the poten-
tially protective effect that elevated dietary protein and
reduced carbohydrate may have on breast cancer
development.
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